Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Senn

Showing results (161-170 of 193) with videos related to

Pageof 20
Sort By:
Deutsche Medizinische Wochenschrift (1946)|December 7, 1979
[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)]A C Mayr, H J Senn, W M Gallmeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88B Thürlimann, K Beretta, M Bacchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2021
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021H J Burstein, G Curigliano, B Thürlimann, et al.
Israel Journal of Medical Sciences|February 1, 1995
The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study GroupA Goldhirsch, R D Gelber, M Castiglione, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study GroupJ Bernhard, C Hürny, A S Coates, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 21, 1999
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patientsM E Sabbioni, M Castiglione, C Hürny, et al.
Toxicology Research|August 10, 2018
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/OmiVilmos Csizmadia, Paul Hales, Christopher Tsu, et al.
Cancer|August 1, 1994
Present and future projects of the International Breast Cancer Study GroupA Goldhirsch, R D Gelber, M Castiglione, et al.
Cell Death Discovery|August 24, 2016
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosisF S Wolenski, C D Fisher, T Sano, et al.
Medical Care|March 1, 1996
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trialC Hürny, J Bernhard, A Coates, et al.
Pageof 20

Showing results (161-170 of 193) with videos related to

Sort By:
Pageof 20
Deutsche Medizinische Wochenschrift (1946)|December 7, 1979
[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)]A C Mayr, H J Senn, W M Gallmeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88B Thürlimann, K Beretta, M Bacchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2021
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021H J Burstein, G Curigliano, B Thürlimann, et al.
Israel Journal of Medical Sciences|February 1, 1995
The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study GroupA Goldhirsch, R D Gelber, M Castiglione, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study GroupJ Bernhard, C Hürny, A S Coates, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 21, 1999
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patientsM E Sabbioni, M Castiglione, C Hürny, et al.
Toxicology Research|August 10, 2018
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/OmiVilmos Csizmadia, Paul Hales, Christopher Tsu, et al.
Cancer|August 1, 1994
Present and future projects of the International Breast Cancer Study GroupA Goldhirsch, R D Gelber, M Castiglione, et al.
Cell Death Discovery|August 24, 2016
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosisF S Wolenski, C D Fisher, T Sano, et al.
Medical Care|March 1, 1996
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trialC Hürny, J Bernhard, A Coates, et al.
Pageof 20